Zacks: Brokerages Expect Achillion Pharmaceuticals, Inc. (ACHN) to Post -$0.15 EPS

Analysts expect Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) to report earnings per share of ($0.15) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Achillion Pharmaceuticals’ earnings. The highest EPS estimate is ($0.15) and the lowest is ($0.16). Achillion Pharmaceuticals reported earnings of ($0.03) per share in the same quarter last year, which would indicate a negative year over year growth rate of 400%. The business is expected to announce its next earnings results on Thursday, February 22nd.

According to Zacks, analysts expect that Achillion Pharmaceuticals will report full year earnings of ($0.61) per share for the current financial year, with EPS estimates ranging from ($0.61) to ($0.60). For the next financial year, analysts forecast that the firm will report earnings of ($0.67) per share, with EPS estimates ranging from ($0.79) to ($0.55). Zacks’ earnings per share calculations are a mean average based on a survey of research firms that that provide coverage for Achillion Pharmaceuticals.

Achillion Pharmaceuticals (NASDAQ:ACHN) last posted its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.04. During the same period in the prior year, the business earned ($0.15) earnings per share.

A number of equities analysts have recently commented on the company. BidaskClub lowered Achillion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, January 13th. Zacks Investment Research lowered Achillion Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, January 2nd. Finally, Leerink Swann restated a “buy” rating and set a $5.00 price target on shares of Achillion Pharmaceuticals in a research note on Monday, December 11th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and three have given a buy rating to the stock. Achillion Pharmaceuticals currently has an average rating of “Hold” and an average target price of $5.13.

Achillion Pharmaceuticals (NASDAQ:ACHN) traded down $0.02 during trading on Tuesday, hitting $2.99. The stock had a trading volume of 1,296,900 shares, compared to its average volume of 2,760,000. The company has a market capitalization of $412.19, a price-to-earnings ratio of -6.10 and a beta of 1.52. Achillion Pharmaceuticals has a twelve month low of $2.69 and a twelve month high of $5.66.

In related news, major shareholder & Johnson Johnson sold 18,367,346 shares of the business’s stock in a transaction dated Monday, November 20th. The stock was sold at an average price of $2.75, for a total transaction of $50,510,201.50. The sale was disclosed in a document filed with the SEC, which is available through this link. Insiders own 7.24% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of ACHN. SG Americas Securities LLC boosted its holdings in Achillion Pharmaceuticals by 18.6% during the second quarter. SG Americas Securities LLC now owns 26,429 shares of the biopharmaceutical company’s stock valued at $121,000 after purchasing an additional 4,144 shares in the last quarter. Legal & General Group Plc boosted its holdings in Achillion Pharmaceuticals by 53.8% during the second quarter. Legal & General Group Plc now owns 42,900 shares of the biopharmaceutical company’s stock valued at $196,000 after purchasing an additional 15,000 shares in the last quarter. Voya Investment Management LLC boosted its holdings in Achillion Pharmaceuticals by 13.7% during the second quarter. Voya Investment Management LLC now owns 55,819 shares of the biopharmaceutical company’s stock valued at $256,000 after purchasing an additional 6,730 shares in the last quarter. UBS Asset Management Americas Inc. boosted its holdings in Achillion Pharmaceuticals by 18.6% during the second quarter. UBS Asset Management Americas Inc. now owns 63,669 shares of the biopharmaceutical company’s stock valued at $292,000 after purchasing an additional 10,000 shares in the last quarter. Finally, OxFORD Asset Management LLP acquired a new stake in Achillion Pharmaceuticals during the second quarter valued at approximately $421,000. Hedge funds and other institutional investors own 76.92% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece of content on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this piece of content can be accessed at https://sportsperspectives.com/2018/01/23/zacks-brokerages-expect-achillion-pharmaceuticals-inc-achn-to-post-0-15-eps.html.

Achillion Pharmaceuticals Company Profile

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Get a free copy of the Zacks research report on Achillion Pharmaceuticals (ACHN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply